Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma.

ABSTRACT: The prognosis for glioblastoma has remained poor despite multimodal standard of care treatment, including temozolomide, radiation, and surgical resection. Further, the addition of immunotherapies, while promising in a number of other solid tumors, has overwhelmingly failed in the treatment of gliomas, in part due to the immunosuppressive microenvironment and poor drug penetrance to the brain. Local delivery of immunomodulatory therapies circumvents some of these challenges and has led to long-term remission in select patients. Many of these approaches utilize convection-enhanced delivery (CED) for immunological drug delivery, allowing high doses to be delivered directly to the brain parenchyma, avoiding systemic toxicity. Here, we review the literature encompassing immunotherapies delivere

SUBMITTER: Sperring CP 

PROVIDER: S-EPMC10195574 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature